---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-319234"
form_type: "8-K"
ticker: "HSCS"
cik: "0001468492"
company_name: "HeartSciences Inc."
filed_at: "2025-12-15T23:59:59+00:00"
generated_at: "2026-05-16T13:12:08.771961+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# HeartSciences reports no Q2 revenue, $2M cash; submits wavECG to FDA

## Summary
- No meaningful revenue for FQ2 2026; cash and equivalents $2.0M, shareholders' equity $4.2M as of Oct 31, 2025.
- MyoVista wavECG device submitted to FDA for 510(k) clearance, a key regulatory milestone.
- MyoVista Insights software platform (MDDS, exempt from 510(k)) launched May 2025; V1.1 released; commercial discussions underway.
- Company plans investor call early 2026 to demonstrate MyoVista Insights software and provide commercialization strategy.
- Algorithms for LVDD assessment separated from device submission due to updated ASE guidelines.

## SEC filing metadata
- accession: 0001193125-25-319234
- form_type: 8-K
- ticker: HSCS
- cik: 0001468492
- company_name: HeartSciences Inc.
- filed_at: 2025-12-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468492/000119312525319234/0001193125-25-319234-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468492/000119312525319234/hscs-20251215.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-319234
- JSON: https://secwatch.observer/filing/0001193125-25-319234.json
- Plain text: https://secwatch.observer/filing/0001193125-25-319234.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.